{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:11:32Z","timestamp":1788901892346,"version":"build-2803163510"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.cca.2026.121183","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:23:52Z","timestamp":1781537032000},"page":"121183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multi-omics body-fluid biomarkers in immunoglobulin a nephropathy: Analytical Validation, standardization, and clinical chemistry translation of diagnostic and prognostic Analytes"],"prefix":"10.1016","volume":"592","author":[{"given":"Vaibhav","family":"Rathore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Asad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chhaya","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Dhyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeshwari","family":"Negi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Dolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.121183_bb0005","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA nephropathy: an interesting autoimmune kidney disease","volume":"361","author":"Rajasekaran","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.cca.2026.121183_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/jcm15052046","article-title":"IgA nephropathy: epidemiology, outcomes, and insights for primary glomerulonephritides","volume":"15","author":"Jakubowska","year":"2026","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cca.2026.121183_bb0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.36469\/jheor.2021.26129","article-title":"A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy","volume":"8","author":"Kwon","year":"2021","journal-title":"J Health Econ Outcomes Res"},{"key":"10.1016\/j.cca.2026.121183_bb0020","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.3390\/ijms25063519","article-title":"Non-invasive biomarkers for diagnosis, risk prediction, and therapy guidance of glomerular kidney diseases: a comprehensive review","volume":"25","author":"Catanese","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121183_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.572754","article-title":"Monitoring immune responses in IgA nephropathy: biomarkers to guide management","volume":"11","author":"Selvaskandan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121183_bb0030","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20178126","article-title":"Data-independent acquisition-based SWATH-MS for quantitative proteomics: a tutorial","volume":"14","author":"Ludwig","year":"2018","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.cca.2026.121183_bb0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10157-018-1582-2","article-title":"Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis","volume":"23","author":"Suzuki","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.cca.2026.121183_bb0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1021\/acs.analchem.9b04651","article-title":"Recent advances in glycoproteomic analysis by mass spectrometry","volume":"92","author":"Suttapitugsakul","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2026.121183_bb0045","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1681\/ASN.2025df55n9v2","article-title":"Revealing the spatial structure of IgA immune complexes in IgAN through volume electron microscopy: TH-PO0679","volume":"36","author":"Si","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2026.121183_bb0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00005-023-00677-w","article-title":"Omics are getting us closer to understanding IgA nephropathy","volume":"71","author":"Mucha","year":"2023","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"key":"10.1016\/j.cca.2026.121183_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2026.02.034","article-title":"Absence of glomerular IgA1 deposition despite overexpression of galactose-deficient IgA1 in the B cell c1galt1 knockout mouse","author":"Wu","year":"2026","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2026.121183_bb0060","first-page":"95","article-title":"Serum and urine galactose deficient-IgA1 as alternative biomarkers in the management of IgA nephropathy","volume":"79","author":"Suleman","year":"2024","journal-title":"Med. J. Malaysia"},{"key":"10.1016\/j.cca.2026.121183_bb0065","article-title":"Serum and urine metabolic fingerprints enable diagnosis and prognosis for IgA nephropathy","volume":"35","author":"Wang","year":"2025","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.cca.2026.121183_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214256","article-title":"Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: a case control study","volume":"14","author":"Bagchi","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.cca.2026.121183_bb0075","doi-asserted-by":"crossref","first-page":"1209394","DOI":"10.3389\/fimmu.2023.1209394","article-title":"Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121183_bb0080","article-title":"Proteomic profiling of IgA nephropathy reveals distinct molecular prognostic subtypes","volume":"26","author":"Chen","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.cca.2026.121183_bb0085","doi-asserted-by":"crossref","first-page":"539","DOI":"10.23876\/j.krcp.23.129","article-title":"Metabolomics profiling: a potential tool for predicting immunoglobulin a nephropathy progression","volume":"42","author":"Kim","year":"2023","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.cca.2026.121183_bb0090","first-page":"1668","article-title":"Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity","volume":"119","author":"Suzuki","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2026.121183_bb0095","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2012010053","article-title":"Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy","volume":"23","author":"Berthoux","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2026.121183_bb0100","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/ki.2012.197","article-title":"The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression","volume":"82","author":"Zhao","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2026.121183_bb0105","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41598-020-57510-z","article-title":"Analysis of O-glycoforms of the IgA1 hinge region by sequential deglycosylation","volume":"10","author":"Ohyama","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.121183_bb0110","article-title":"Diagnostic potential of plasma IgA1 O-glycans in discriminating IgA nephropathy from other glomerular diseases and healthy participants","volume":"9","author":"Zhang","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.cca.2026.121183_bb0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2144\/btn-2018-0042","article-title":"Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients","volume":"65","author":"Reily","year":"2018","journal-title":"Biotechniques"},{"key":"10.1016\/j.cca.2026.121183_bb0120","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/ndt\/gfv221","article-title":"Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy","volume":"30","author":"Yasutake","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2026.121183_bb0125","article-title":"Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy","volume":"7","author":"Kim","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.cca.2026.121183_bb0130","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ekir.2017.11.015","article-title":"Progressive IgA nephropathy is associated with low circulating mannan-binding lectin-associated serine protease-3 and increased glomerular factor H-related protein-5 deposition","volume":"3","author":"Medjeral-Thomas","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.cca.2026.121183_bb0135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12014-017-9165-x","article-title":"Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy","volume":"14","author":"Paunas","year":"2017","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.cca.2026.121183_bb0140","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.3390\/jcm11144231","article-title":"Associations between biomarkers of complement activation, galactose-deficient IgA1 antibody and the updated Oxford pathology classification of IgA nephropathy","volume":"11","author":"Juan","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cca.2026.121183_bb0145","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.15125","article-title":"Urinary complement proteins in IgA nephropathy progression from a relative quantitative proteomic analysis","volume":"11","author":"Niu","year":"2023","journal-title":"PeerJ"},{"key":"10.1016\/j.cca.2026.121183_bb0150","doi-asserted-by":"crossref","first-page":"1117995","DOI":"10.3389\/fimmu.2023.1117995","article-title":"Urinary complement profile in IgA nephropathy and its correlation with the clinical and pathological characteristics","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121183_bb0155","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40364-024-00619-4","article-title":"Blood and urine biomarkers of disease progression in IgA nephropathy","volume":"12","author":"Duan","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.cca.2026.121183_bb0160","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1074\/mcp.M114.039693","article-title":"Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin a nephropathy and healthy individuals","volume":"13","author":"Lehoux","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.cca.2026.121183_bb0165","article-title":"DNA methylation in Cosmc promoter region and aberrantly glycosylated IgA1 associated with pediatric IgA nephropathy","volume":"10","author":"Sun","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.cca.2026.121183_bb0170","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.kint.2017.10.019","article-title":"IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis","volume":"93","author":"Suzuki","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2026.121183_bb0175","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5114\/ceji.2018.77386","article-title":"Serum GDIgA1 levels in children with IgA nephropathy and Henoch-Sch\u00f6nlein nephritis","volume":"43","author":"Mizerska-Wasiak","year":"2018","journal-title":"Cent Eur J Immunol"},{"key":"10.1016\/j.cca.2026.121183_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206865","article-title":"Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy","volume":"13","author":"Wada","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.cca.2026.121183_bb0185","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.3390\/jcm11113173","article-title":"Galactose-deficient IgA1 as a candidate urinary marker of IgA nephropathy","volume":"11","author":"Fukao","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cca.2026.121183_bb0190","doi-asserted-by":"crossref","DOI":"10.11613\/BM.2019.020705","article-title":"European survey on preanalytical sample handling - part 2: practices of European laboratories on monitoring and processing haemolytic, icteric and lipemic samples","volume":"29","author":"Cadamuro","year":"2019","journal-title":"Biochem. Med."},{"key":"10.1016\/j.cca.2026.121183_bb0195","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.rinim.2012.08.002","article-title":"In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells","volume":"2","author":"Yanagihara","year":"2012","journal-title":"Results Immunol"},{"key":"10.1016\/j.cca.2026.121183_bb0200","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s10157-013-0921-6","article-title":"Serum levels of galactose-deficient immunoglobulin A1 and related immune complex are associated with disease activity of IgA nephropathy","volume":"18","author":"Suzuki","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.cca.2026.121183_bb0205","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/ckj\/sfy068","article-title":"Higher serum galactose-deficient immunoglobulin A1 concentration is associated with stronger mesangial cellular inflammatory response and more severe histologic findings in immunoglobulin a nephropathy","volume":"12","author":"Nguyen","year":"2019","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.cca.2026.121183_bb0210","article-title":"Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression","volume":"14","author":"Maixnerova","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.cca.2026.121183_bb0215","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1159\/000502579","article-title":"Clinical significance of galactose-deficient IgA1 by KM55 in patients with IgA nephropathy","volume":"44","author":"Zhang","year":"2019","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.cca.2026.121183_bb0220","doi-asserted-by":"crossref","first-page":"4284379","DOI":"10.1155\/2020\/4284379","article-title":"Clinical significance of serum galactose-deficient IgA1 level in children with IgA nephropathy","volume":"2020","author":"Irabu","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cca.2026.121183_bb0225","doi-asserted-by":"crossref","first-page":"17147","DOI":"10.1038\/s41598-022-22116-0","article-title":"Assessment of variability in the plasma 7k SomaScan proteomics assay","volume":"12","author":"Candia","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.121183_bb0230","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/pmic.201000443","article-title":"Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy","volume":"11","author":"Moon","year":"2011","journal-title":"Proteomics"},{"key":"10.1016\/j.cca.2026.121183_bb0235","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/ndt\/gfw337","article-title":"Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis","volume":"32","author":"Siwy","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2026.121183_bb0240","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/gfaa307","article-title":"Urine proteomics for prediction of disease progression in patients with IgA nephropathy","volume":"37","author":"Rudnicki","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2026.121183_bb0245","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf344","article-title":"Serum proteome analysis detects early molecular signatures of disease progression in IgA nephropathy","volume":"18","author":"Chen","year":"2025","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.cca.2026.121183_bb0250","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12014-022-09387-5","article-title":"LC-MS\/MS based metabolomics and proteomics reveal candidate biomarkers and molecular mechanism of early IgA nephropathy","volume":"19","author":"Zhang","year":"2022","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.cca.2026.121183_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080830","article-title":"Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography","volume":"8","author":"Kalantari","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.cca.2026.121183_bb0260","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20452\/pamw.2345","article-title":"Complement components, proteolysis-related, and cell communication-related proteins detected in urine proteomics are associated with IgA nephropathy","volume":"124","author":"Mucha","year":"2014","journal-title":"Pol. Arch. Med. Wewn."},{"key":"10.1016\/j.cca.2026.121183_bb0265","doi-asserted-by":"crossref","first-page":"3650909","DOI":"10.1155\/2016\/3650909","article-title":"Toward noninvasive diagnosis of IgA nephropathy: a pilot urinary metabolomic and proteomic study","volume":"2016","author":"Neprasova","year":"2016","journal-title":"Dis. Markers"},{"key":"10.1016\/j.cca.2026.121183_bb0270","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12882-019-1598-1","article-title":"Characterization of glomerular extracellular matrix in IgA nephropathy by proteomic analysis of laser-captured microdissected glomeruli","volume":"20","author":"Paunas","year":"2019","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.cca.2026.121183_bb0275","doi-asserted-by":"crossref","first-page":"17208","DOI":"10.1021\/acsomega.4c07827","article-title":"Proteomic insights into IgA nephropathy: a comprehensive analysis of differentially expressed proteins in the kidney","volume":"10","author":"Huang","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.cca.2026.121183_bb0280","doi-asserted-by":"crossref","first-page":"363","DOI":"10.6061\/clinics\/2012(04)10","article-title":"A proton nuclear magnetic resonance-based metabonomics study of metabolic profiling in immunoglobulin a nephropathy","volume":"67","author":"Sui","year":"2012","journal-title":"Clinics"},{"key":"10.1016\/j.cca.2026.121183_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078531","article-title":"Distinct metabolic profile of primary focal segmental glomerulosclerosis revealed by NMR-based metabolomics","volume":"8","author":"Hao","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.cca.2026.121183_bb0290","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mrc.4573","article-title":"1H NMR-based metabolomics study for identifying urinary biomarkers and perturbed metabolic pathways associated with severity of IgA nephropathy: a pilot study","volume":"55","author":"Kalantari","year":"2017","journal-title":"Magn. Reson. Chem."},{"key":"10.1016\/j.cca.2026.121183_bb0295","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1111\/jcmm.16520","article-title":"Comprehensive metabolomic profiling in early IgA nephropathy patients reveals urine glycine as a prognostic biomarker","volume":"25","author":"Park","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.cca.2026.121183_bb0300","doi-asserted-by":"crossref","first-page":"591","DOI":"10.23876\/j.krcp.22.146","article-title":"Serum and urine metabolomic biomarkers for predicting prognosis in patients with immunoglobulin a nephropathy","volume":"42","author":"Jeon","year":"2023","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.cca.2026.121183_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/metabo9070123","article-title":"NMR spectroscopy for metabolomics research","volume":"9","author":"Emwas","year":"2019","journal-title":"Metabolites"},{"key":"10.1016\/j.cca.2026.121183_bb0310","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/metabo10060229","article-title":"Recommendations and best practices for standardizing the pre-analytical processing of blood and urine samples in metabolomics","volume":"10","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.cca.2026.121183_bb0315","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11306-022-01926-3","article-title":"Quality assurance and quality control reporting in untargeted metabolic phenotyping: mQACC recommendations for analytical quality management","volume":"18","author":"Kirwan","year":"2022","journal-title":"Metabolomics"},{"key":"10.1016\/j.cca.2026.121183_bb0320","first-page":"565","article-title":"Lipidomics reveals association of circulating lipids with body mass index and outcomes in IgA nephropathy patients","volume":"13","author":"Deng","year":"2021","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.cca.2026.121183_bb0325","article-title":"Association between 1400 metabolites and IgA nephropathy: a Mendelian randomization analysis","volume":"104","author":"Wang","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.cca.2026.121183_bb0330","article-title":"The clinical value of metabolic indicators in immunoglobulin a nephropathy","volume":"13","author":"Zhao","year":"2026","journal-title":"Front. Med."},{"key":"10.1016\/j.cca.2026.121183_bb0335","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/ndt\/gfv232","article-title":"Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients","volume":"31","author":"Pesce","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2026.121183_bb0340","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.compbiomed.2015.09.003","article-title":"Patient classification and outcome prediction in IgA nephropathy","volume":"66","author":"Diciolla","year":"2015","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.cca.2026.121183_bb0345","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.ajkd.2019.02.016","article-title":"Prediction and risk stratification of kidney outcomes in IgA nephropathy","volume":"74","author":"Chen","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.cca.2026.121183_bb0350","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.kint.2020.07.046","article-title":"Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin a nephropathy","volume":"99","author":"Schena","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2026.121183_bb0355","first-page":"436","article-title":"Development and validation of a machine learning-based prognostic model for IgA nephropathy with chronic kidney disease stage 3 or 4","volume":"10","author":"Yu","year":"2024","journal-title":"Kidney Dis"},{"key":"10.1016\/j.cca.2026.121183_bb0360","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00281-021-00847-y","article-title":"How will artificial intelligence and bioinformatics change our understanding of IgA nephropathy in the next decade?","volume":"43","author":"B\u00fclow","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.cca.2026.121183_bb0365","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.cca.2026.121183_bb0370","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1093\/ndt\/gfp273","article-title":"A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study","volume":"24","author":"Goto","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2026.121183_bb0375","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in IgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2026.121183_bb0380","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/ndt\/gfac004","article-title":"Rapidly progressive IgA nephropathy: clinicopathological characteristics and outcomes assessed according to the revised definition of the KDIGO 2021 guideline","volume":"37","author":"Yu","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2026.121183_bb0385","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.2147\/JIR.S512916","article-title":"Novel biomarkers as non-invasive diagnostic tools in IgA nephropathy: a comparative study with lupus nephritis and membranous nephropathy","volume":"18","author":"Liu","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.cca.2026.121183_bb0390","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.ekir.2023.09.020","article-title":"Evaluating progression risk in patients with immunoglobulin a nephropathy","volume":"8","author":"Cattran","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.cca.2026.121183_bb0395","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/ndt\/gfr403","article-title":"Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients","volume":"27","author":"Sato","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2026.121183_bb0400","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.kint.2021.04.026","article-title":"Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy","volume":"100","author":"Kano","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2026.121183_bb0405","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1681\/ASN.2021060815","article-title":"Intensity of macrophage infiltration in glomeruli predicts response to immunosuppressive therapy in patients with IgA nephropathy","volume":"32","author":"Xie","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2026.121183_bb0410","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part a of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin a nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2026.121183_bb0415","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf203","article-title":"Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide","volume":"18","author":"Chen","year":"2025","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.cca.2026.121183_bb0420","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121183_bb0425","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:48:07Z","timestamp":1788900487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126003657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":85,"alternative-id":["S0009898126003657"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121183","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-omics body-fluid biomarkers in immunoglobulin a nephropathy: Analytical Validation, standardization, and clinical chemistry translation of diagnostic and prognostic Analytes","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121183"}}